drugset / Trial / NCT00394901
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.
Timeline
- Start
- 2006-09
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pregabalin | Small molecule | 150 mg | Oral |
| Subject | Pregabalin | Small molecule | 300 mg | Oral |
| Subject | Pregabalin | Small molecule | 600 mg | Oral |